Related Case Studies
A First of its Kind Approval Changes the Way We Think About Access
A clinical-stage pharmaceutical company faced a unique barrier in bringing its first product to market—seeking pan-tumor approval based on a genetic marker, rather than a traditional approval based on cancer type. They subsequently sought recognition for the product across relevant clinical compendia.
View All Case Studies
- Assessing Market Potential
- MSL Trainings
- Conference Engagement Strategy
- KOL Development
- Guideline Advocacy Strategy
- Clinical Guideline Strategy
- Engaging Community and Academic Physicians in Preparation for Product Launch
- Understanding the Patient Journey and Pain Points in Diagnosis
- Collecting KOL Insights Into Trial Design
- Healthcare Policy Changes Interpreted in Real-Time
- A Comprehensive Launch Strategy Leads to Broad Access
- Understanding the European Market
- Insight Into a New Therapeutic Landscape
- Strategizing a Change in a Company’s Focus
- A Novel Therapy Seeks to Support Physician Reimbursement
- The Case is Made for New CPT Codes
- A Successful Transition from Europe to the US Market
- A First of its Kind Approval Changes the Way We Think About Access
